Neurava Enhances Board with Industry Leaders for Future in Epilepsy Care

Neurava Enhances Its Leadership Team

Neurava, an innovative company on the cutting edge of epilepsy care and medical device technology, has announced significant changes to its Board of Directors. Industry veterans Daniel (Dan) Moore and Jed Kay are joining the team, each bringing a wealth of experience that promises to enhance the company’s mission of improving epilepsy management.

The New Board Members

Daniel Moore

Dan Moore, a well-recognized figure in the medical device sector, previously served as CEO of Cyberonics, a company known for its innovative epilepsy treatment solutions. During his tenure, Moore drove the company’s revenue growth from approximately $100 million to $300 million, exemplifying his capacity for leadership and strategic innovation. He later transitioned to become Chairman of LivaNova, following the merger of Cyberonics and Sorin, where he continued to promote advancements in neuromodulation therapies for epilepsy.

Jed Kay

Jed Kay adds another layer of expertise to Neurava’s Board. As an Operating Partner with Elevate Ventures, he has collaborated with numerous healthcare startups, equipping them with the knowledge to tackle complex sales and reimbursement issues. His insights into market access and commercialization strategies will be invaluable as Neurava embarks on its next phase of growth.

Vision for the Future

The addition of Dan and Jed to Neurava’s leadership team aligns with the company’s strategic goals. Co-Founder and CEO Jay Shah expressed enthusiasm about their appointments, emphasizing that their combined experiences will play a pivotal role in scaling the company’s operations and impact in epilepsy care.

Vivek Ganesh, Co-Founder and CTO, pointed out that their guidance will sharpen Neurava's focus on developing data-driven, patient-centered solutions, primarily through their innovative wearable technologies. Such advancements aim to enhance the lives of those affected by epilepsy, reflecting the core mission of the company.

Impact on Epilepsy Care

Both new directors are committed to transforming the landscape of epilepsy treatment. Dan Moore stated his excitement about joining Neurava during a critical period. He highlighted that there exists a tremendous opportunity to elevate the quality of life for individuals battling epilepsy, an area where Neurava is striving to make significant contributions.

Jed Kay echoed similar sentiments, elaborating on the potential of Neurava’s wearable technology to meet critical needs among patients with uncontrolled seizures. He is eager to collaborate closely with the Board and Neurava's team to innovate monitoring solutions, enhancing engagement and support among patients, caregivers, and healthcare providers.

About Neurava

Neurava is positioned as a MedTech startup that is pioneering the development of wearable devices capable of monitoring seizures and other related health risks. Their patient-centric approach is evident in the design of their unique platform, which seeks to address the pressing needs of millions facing epilepsy across the globe. As they continue to evolve, Neurava remains devoted to delivering transformative healthcare solutions designed to empower patients and improve their daily lives.

In conclusion, with seasoned professionals like Dan Moore and Jed Kay aboard, Neurava is poised for a promising future in epilepsy care, driving innovations that aim to make a meaningful difference in the lives of patients worldwide. For further information about Neurava and their groundbreaking work in epilepsy management, you can visit their website here.